KUNMING, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (“China Shenghuo,” “the Company”) , which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People’s Republic of China (“PRC”), today announced that Lei Lan, Executive Director of Sales, and Qionghua Gao, Chief Financial Officer, are scheduled to present at the Roth Capital Partners 2007 New York Conference.
The Roth Capital Partners 2007 New York Conference is a two-day event featuring presentations and one-on-one meetings with more than 230 small and microcap growth companies in a variety of industries.
Date: Thursday, September 6, 2007 Time: 12:00 p.m. EDT Venue: The Westin New York at Times Square Live webcast: http://www.wsw.com/webcast/roth13/csheng/
A replay of the webcast will be available for 90 days beginning the afternoon of the presentation.
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. (“China Shenghuo” or “the Company”) is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd (“Kunming Shenghuo”), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500 drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors include, but are not limited to, the company’s reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company’s intellectual property rights, market acceptance of the company’s products, changes in the laws of the People’s Republic of China that affect the company’s operations, any recurrence of severe acute respiratory syndrome or avian flu, the company’s ability to obtain all necessary government certifications and/or licenses to conduct the company’s business, development of a public trading market for the company’s securities, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company’s operations and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact: Ms. Gao Qionghua, CFO China Shenghuo Pharmaceutical Holdings, Inc. Tel: +86-871-7282608 Email: qionghua_kmsh@163.com Crocker Coulson, President CCG Elite Investor Relations Tel: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com
China Shenghuo Pharmaceutical Holdings, Inc.
CONTACT: Gao Qionghua, CFO of China Shenghuo Pharmaceutical Holdings,Inc., +86-871-7282608, or qionghua_kmsh@163.com; Crocker Coulson, Presidentof CCG Elite Investor Relations, +1-646-213-1915, orcrocker.coulson@ccgir.com
